Shandong Oriental Ocean Sci-Tech Co.,Ltd. (002086.SZ) has announced that its wholly-owned subsidiary, Aiweike Biotechnology Co., Ltd., has recently obtained registration approval from the Shandong Medical Products Administration for two of its self-developed testing kits. The approved products are the β-Collagen Specific Sequence (β-CTx) Assay Kit (Magnetic Particle Chemiluminescence Method) and the Total Type I Collagen Amino-Terminal Propeptide (Total-P1NP) Assay Kit (Magnetic Particle Chemiluminescence Method), both of which have been granted medical device registration certificates. Aiweike Biotechnology Co., Ltd. currently has a minor impact on the company's overall performance. The commencement of production for the newly approved kits and their potential subsequent impact on the company's financial performance remain uncertain. Investors are advised to be aware of the associated investment risks.